This clinical reference guide is designed for clinicians, advanced practice providers, and clinical educators to optimize the identification, staging, and comprehensive management of Chronic Kidney Disease (CKD) within the contemporary Cardiovascular-Kidney-Metabolic (CKM) framework.
In the clinical evaluation of patients with kidney impairment, immediate emergency department or inpatient triage is required upon presentation of the following critical clinical red flags:
Chronic Kidney Disease is defined by the persistent presence of structural or functional kidney abnormalities for three months or longer, with clear implications for health[1:2]. Crucially, CKD cannot be diagnosed from a single laboratory result; persistence over at least a 3-month window must be documented to exclude transient fluctuations.
The diagnostic criteria require at least one of the following markers of kidney damage to persist for ≥ 3 months[1:3]:
A clear diagnostic distinction must be maintained between CKD and Acute Kidney Injury:
The KDIGO classification system represents the gold standard for predicting cardiorenal risk, combining eGFR categories (G1 to G5) with Albuminuria categories (A1 to A3)[1:7]. Predicting outcomes based on eGFR alone is clinically insufficient; the risk of progressive kidney failure, cardiovascular events, and mortality escalates significantly at higher stages of albuminuria for any given level of eGFR.
| Category | eGFR (mL/min/1.73 m²) | Clinical Description |
|---|---|---|
| G1 | ≥ 90 | Normal or high kidney function |
| G2 | 60–89 | Mildly decreased kidney function |
| G3a | 45–59 | Mildly to moderately decreased kidney function |
| G3b | 30–44 | Moderately to severely decreased kidney function |
| G4 | 15–29 | Severely decreased kidney function |
| G5 | < 15 | Kidney failure (add 'D' if dialysis-dependent) |
| Category | UACR (mg/g) | UACR (mg/mmol) | Clinical Description |
|---|---|---|---|
| A1 | < 30 | < 3 | Normal to mildly increased |
| A2 | 30–300 | 3–30 | Moderately increased (formerly "microalbuminuria") |
| A3 | > 300 | > 30 | Severely increased (formerly "macroalbuminuria") |
The intersection of these categories defines four risk tiers representing the hazard for kidney progression, MACE, and all-cause mortality[1:8]:
CKD is a heterogeneous condition arising from several distinct primary etiologies, each requiring tailored clinical diagnostic and therapeutic approaches[1:9][9]:
The American Heart Association (AHA) CKM syndrome framework highlights the systemic, bidirectional connections among metabolic risk factors, CKD, and the cardiovascular system[13]. Chronic kidney disease directly accelerates cardiovascular pathology through multiple pathways:
Foundational disease-modifying therapies for CKM and CKD are evaluated below based on their ability to slow kidney progression and reduce clinical hard endpoints.
| Intervention | Clinical Utility | Evidence Quality | Key Outcomes | Notes & Citations |
|---|---|---|---|---|
| RAS Blockade (ACEi or ARB) | First-line therapy for hypertensive patients with CKD and albuminuria. | High (GRADE: High) | Delays onset of kidney failure and reduces cardiovascular events. | Titrate to maximally tolerated doses; do not combine ACEi and ARB due to hyperkalemia risk[21][2:2]. |
| SGLT2 Inhibition | Foundational cardiorenal protection in diabetic and non-diabetic CKD. | High (GRADE: High) | Halves chronic eGFR decline rate and reduces MACE/all-cause mortality. | Effective down to eGFR of 20 mL/min/1.73 m²; consistent across frailty tiers[4:1][22][23][24][25]. |
| Nonsteroidal MRA (Finerenone) | Add-on therapy for persistent albuminuria in type 2 diabetes and CKD. | High (GRADE: High) | Reduces composite renal and heart failure outcomes. | Lower risk of hyperkalemia than steroidal MRAs[26]; efficacy is independent of SGLT2i use[6:1][27]. |
| GLP-1 Receptor Agonists (Semaglutide) | High-impact glycemic control and cardiorenal risk reduction. | High (GRADE: High) | 24% reduction in primary kidney events; 20% reduction in all-cause mortality. | Based on the landmark FLOW trial in patients with T2D and CKD[5:2][18:2][28]. |
| Standardized BP Control (SBP < 120 mmHg) | Primary hemodynamic target to preserve kidney function. | High (GRADE: High) | Reduces cardiovascular mortality and slows renal decline. | Dependent on standardized office BP measurement techniques; relax targets in frail patients[29][14:1][30]. |
A regular, systematic medication review is vital for patients with CKD to prevent drug-induced kidney injury and optimize safety[1:12].
Nutritional interventions must be tailored dynamically based on laboratory values, CKD staging, and the underlying etiology of kidney disease[1:16].
As renal function declines, multiple systemic complications arise due to the loss of endocrine, metabolic, and excretory capacity[1:18].
Primary care providers should coordinate a timely nephrology referral when patients meet any of the following high-risk thresholds[1:22]:
When patients reach end-stage kidney disease (Stage G5, typically eGFR < 10–15 mL/min/1.73 m² accompanied by uremic symptoms), kidney replacement therapy is indicated[39]:
Kidney transplantation represents the optimal therapeutic modality for suitable candidates with ESKD[39:3].
For patients with advanced age, high frailty indexes, or severe cognitive or physical comorbidities who choose not to pursue invasive KRT, supportive care (conservative management) represents a highly structured, evidence-based alternative clinical pathway[39:4].
When evaluating clinical trials and literature in nephrology, clinicians must maintain a strict methodological distinction between surrogate markers of kidney function and clinical hard endpoints.
Surrogate markers are early biochemical indicators utilized to predict long-term clinical paths. While highly valuable for early drug screening and monitoring individual patient response, they do not directly measure patient survival or organ loss:
Hard endpoints measure definitive, life-altering events. Clinical guidelines and regulatory approvals are fundamentally built on a drug's demonstrated ability to reduce these hard endpoints:
For a patient presenting with metabolic risk factors (diabetes, obesity, hypertension) or suspected kidney impairment, the following structured clinical sequence should be initiated:
Longevipedia pages are AI-updated and human-reviewed. We prioritize human evidence, cite claims, and update pages when the evidence changes.
Awdishu L, Maxson R, Gratt C. KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know. American Journal of Health-System Pharmacy. 2025. https://pubmed.ncbi.nlm.nih.gov/40197825/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Zac-Varghese S, Winocour P. Managing diabetic kidney disease. British Medical Bulletin. 2018. https://pubmed.ncbi.nlm.nih.gov/29216336/ ↩︎ ↩︎ ↩︎ ↩︎
Navaneethan SD, Zoungas S, Caramori ML. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. Annals of Internal Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/36623286/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Heerspink HJL, Stefánsson BV, Correa-Rotter R. Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine. 2020. https://pubmed.ncbi.nlm.nih.gov/32970396/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Perkovic V, Tuttle KR, Rossing P. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England Journal of Medicine. 2024. https://pubmed.ncbi.nlm.nih.gov/38785209/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Neuen BL, Heerspink HJL, Perkovic V. Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY). Lancet. 2026. https://pubmed.ncbi.nlm.nih.gov/42248158/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Chang AR, Evans M, Yule C. Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study. BMC Nephrology. 2016. https://pubmed.ncbi.nlm.nih.gov/27825313/ ↩︎
Johnson HN, Prasad-Reddy L. Updates in Chronic Kidney Disease. Journal of Pharmacy Practice. 2024. https://pubmed.ncbi.nlm.nih.gov/38877746/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
EMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. The Lancet Diabetes & Endocrinology. 2024. https://pubmed.ncbi.nlm.nih.gov/38061372/ ↩︎
Martinez Leon V, Hilburg R, Susztak K. Mechanisms of diabetic kidney disease and established and emerging treatments. Nature Reviews Endocrinology. 2026. https://pubmed.ncbi.nlm.nih.gov/40935879/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Wheeler DC, Toto RD, Stefánsson BV. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International. 2021. https://pubmed.ncbi.nlm.nih.gov/33878338/ ↩︎
Wheeler DC, Jongs N, Stefansson BV. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrology Dialysis Transplantation. 2022. https://pubmed.ncbi.nlm.nih.gov/34850160/ ↩︎
Vaduganathan M, Filippatos G, Claggett BL. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nature Medicine. 2024. https://pubmed.ncbi.nlm.nih.gov/39218030/ ↩︎ ↩︎
Drawz PE, Beddhu S, Bignall ONR 2nd. KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. American Journal of Kidney Diseases. 2022. https://pubmed.ncbi.nlm.nih.gov/35063302/ ↩︎ ↩︎ ↩︎ ↩︎
Mann JFE, Chang TI, Cushman WC. Commentary on the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD. Current Cardiology Reports. 2021. https://pubmed.ncbi.nlm.nih.gov/34398316/ ↩︎ ↩︎
Mayne KJ, Staplin N, Keane DF. Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD. Journal of the American Society of Nephrology. 2024. https://pubmed.ncbi.nlm.nih.gov/38082486/ ↩︎
Kosiborod MN, Deanfield J, Pratley R. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024. https://pubmed.ncbi.nlm.nih.gov/39222642/ ↩︎
Pratley RE, Tuttle KR, Rossing P. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. Journal of the American College of Cardiology. 2024. https://pubmed.ncbi.nlm.nih.gov/39217553/ ↩︎ ↩︎ ↩︎
Ostrominski JW, Filippatos G, Claggett BL. Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction: A FINE-HEART Analysis. JACC Heart Failure. 2025. https://pubmed.ncbi.nlm.nih.gov/40505158/ ↩︎ ↩︎
Wexler DJ, Garvey WT, Ghosh A. Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial. Diabetes Care. 2025. https://pubmed.ncbi.nlm.nih.gov/40267365/ ↩︎
Wheeler DC, Becker GJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney International. 2013. https://pubmed.ncbi.nlm.nih.gov/23325075/ ↩︎ ↩︎
EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N. Empagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/36331190/ ↩︎ ↩︎
Mayne KJ, Sardell RJ, Staplin N. Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial. Clinical Journal of the American Society of Nephrology. 2024. https://pubmed.ncbi.nlm.nih.gov/40179340/ ↩︎
EMPA-KIDNEY Collaborative Group. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. The Lancet Diabetes & Endocrinology. 2024. https://pubmed.ncbi.nlm.nih.gov/38061371/ ↩︎ ↩︎ ↩︎
Vart P, Butt JH, Jongs N. Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty. The Journals of Gerontology Series A. 2024. https://pubmed.ncbi.nlm.nih.gov/37527836/ ↩︎
Agarwal R, Pitt B, Palmer BF. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clinical Kidney Journal. 2023. https://pubmed.ncbi.nlm.nih.gov/36864892/ ↩︎
Agarwal R, Filippatos G, Pitt B. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal. 2022. https://pubmed.ncbi.nlm.nih.gov/35023547/ ↩︎ ↩︎ ↩︎
Tuttle KR, Mann JFE, Mayrdorfer MM. Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial. Clinical Journal of the American Society of Nephrology. 2026. https://pubmed.ncbi.nlm.nih.gov/41706532/ ↩︎
Taler SJ, Agarwal R, Bakris GL. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. American Journal of Kidney Diseases. 2013. https://pubmed.ncbi.nlm.nih.gov/23684145/ ↩︎
See EJ, Cullen V, Caring for Australians and New Zealanders with Kidney Impairment (CARI) Guideline Group. Commentary on the 2021 update of the KDIGO clinical practice guideline for management of blood pressure in chronic kidney disease. Nephrology (Carlton). 2025. https://pubmed.ncbi.nlm.nih.gov/39725407/ ↩︎ ↩︎ ↩︎
Fernández-Fernandez B, Sarafidis P, Soler MJ. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clinical Kidney Journal. 2023. https://pubmed.ncbi.nlm.nih.gov/37529652/ ↩︎
MacIsaac RJ. Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome. Future Cardiology. 2025. https://pubmed.ncbi.nlm.nih.gov/40458885/ ↩︎ ↩︎
Ruzicka M, Quinn RR, McFarlane P. Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for the management of blood pressure in CKD. American Journal of Kidney Diseases. 2014. https://pubmed.ncbi.nlm.nih.gov/24725980/ ↩︎
Verbeke F, Lindley E, Van Bortel L. A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application. Nephrology, Dialysis, Transplantation. 2014. https://pubmed.ncbi.nlm.nih.gov/24071661/ ↩︎
Mottl AK, Alicic R, Argyropoulos C. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. American Journal of Kidney Diseases. 2022. https://pubmed.ncbi.nlm.nih.gov/35144840/ ↩︎
Fletcher RA, Jongs N, Chertow GM. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials. Journal of the American Society of Nephrology. 2023. https://pubmed.ncbi.nlm.nih.gov/37876229/ ↩︎ ↩︎
Weinmann-Menke J, Galle J. [Progression inhibition in chronic kidney disease]. Innere Medizin (Heidelberg). 2026. https://pubmed.ncbi.nlm.nih.gov/42397586/ ↩︎
Montero N, Oliveras L, Martínez-Castelao A. Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology. Nefrologia. 2025. https://pubmed.ncbi.nlm.nih.gov/40222774/ ↩︎
Streja E, Nicholas SB, Norris KC. Controversies in timing of dialysis initiation and the role of race and demographics. Seminars in Dialysis. 2013. https://pubmed.ncbi.nlm.nih.gov/24102770/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Herrington WG, Che ZJ, Sardell R. Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis. The Lancet Diabetes & Endocrinology. 2025. https://pubmed.ncbi.nlm.nih.gov/41082889/ ↩︎
Agarwal R, Tu W, Farjat AE. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis. Annals of Internal Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/38048573/ ↩︎